ClinicalTrials.gg
RecruitingNCT07360080AL1GNUpdated Nov 9, 2026

Long-Term Outcomes of Teplizumab in Routine Clinical Care

An observational study in Type 1 Diabetes, sponsored by Sanofi. Recruiting at 12 sites in 4 countries. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Sanofi · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 9, 2026First site in Germany2 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies in Diabetes Mellitus, Type 1 by Sanofi — 6 open to participants now, 9 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · Sanofi.

Started
2026
with 1 other
Observational
6 of 67
4 open now
Registered
66th of 67
by date

Among the 67 studies in Diabetes Mellitus, Type 1 by Sanofi, this one is one of 2 that started in 2026, is one of 6 observational ones, and was the 66th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

6 of the 67 studies in Diabetes Mellitus, Type 1 by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Diabetes Mellitus, Type 1 by Sanofi, or all of them as a file.
02

Study summary

This is an observational, prospective cohort study designed to evaluate the outcomes after teplizumab treatment in participants with Stage 2 Type 1 Diabetes (T1D) for delaying the onset of Stage 3 T1D. The study will monitor participants receiving teplizumab as part of routine clinical care across multiple sites. Additionally, patient-reported outcomes (PROs) will be evaluated to further assess the treatment's impact on participant's quality of life including emotional and psychosocial aspects associated with T1D. This approach will provide a more comprehensive understanding of how the treatment performs over time and across diverse patient populations, providing valuable insights into the sustained effects of teplizumab and offering a real world picture of its impact on the long-term management of T1D.

Read the detailed description

Enrolled participants will be followed for up to 10 years depending on the time the participants are included after initiating teplizumab treatment.

03

Conditions studied

  • Type 1 Diabetes
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with Stage 2 T1D who have received at least 1 teplizumab infusion within 6 weeks prior to enrollment. Approximately 1000 participants, in 85 sites across 19 countries will be enrolled over 5 years.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who have received at least 1 teplizumab infusion within 6 weeks prior to enrollment.
  • Participants must have a confirmed diagnosis of Stage 2 T1D according to the treating physician at the time of the first infusion of teplizumab.

(Note: Participants who progress to Stage 3 T1D by Week 6 will still be eligible, provided they were in Stage 2 at the time of the first teplizumab infusion.)

  • Participants (or their legal guardians, as applicable) who provide appropriate written or electronic /assent as applicable for the age of the participant and as per local regulations.

Exclusion criteria

Exclusion Criteria -

  • Participants who had participated in a previous clinical trial for teplizumab.
  • Participants enrolled in a clinical trial within 6 months prior to study enrollment.

(Note: Participants enrolled in other observational studies may be included.)

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with Stage 2 Type 1 Diabetes (T1D) who received Teplizumab

    Drug: Teplizumab

Interventions

  • This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.

06

What researchers measure

Primary outcomes

  1. Time from teplizumab infusion start to the onset of Stage 3 T1D

    Time frame: From start of infusion to maximum of 10 years

Secondary outcomes

  1. Proportion of participants who complete teplizumab treatment course

    Time frame: Up to end of infusion, maximum of 5 years

  2. Number of participants with adverse events during the infusion period

    Time frame: Till 6 weeks post last infusion, maximum of 5 years

  3. Number of participants with adverse events of special interest and serious adverse events

    Time frame: From 6 weeks post last infusion through the follow-up, maximum of 10 years

  4. Number of participants with T1D-related complications

    Including but not limited to the following: diabetic ketoacidosis, severe hypoglycemia, retinopathy, nephropathy, neuropathy, cardiovascular events

    Time frame: From infusion up to end of study, maximum of 10 years

  5. Glycemic control assessment values

    Time frame: From baseline through follow-up, maximum of 10 years

  6. Change from baseline in glycated hemoglobin (HbA1c)

    Time frame: From baseline through follow-up, maximum of 10 years

  7. Proportion of participants achieving target HbA1c ≤ 6.5%

    Time frame: From baseline through follow-up, maximum of 10 years

  8. Proportion of participants using home glycemic control assessments (eg, SMBG, CGM)

    Time frame: From baseline through follow-up, maximum of 10 years

  9. Proportion of participants using glycemic control assessments in-clinic (eg, OGTT, FPG, MMTT, RPG)

    Time frame: From baseline through follow-up, maximum of 10 years

  10. Mean change from baseline in Time in range (TIR) (70 to 180 mg/dL [3.9 to 10 mmol/L])

    CGM reading 70 to 180 mg/dL \[3.9 to 10 mmol/L\]

    Time frame: From baseline through follow-up, maximum of 10 years

  11. Mean change from baseline in Time in tight range (TITR) (70 to 140 mg/dL [3.9 to 7.8 mmol/L])

    CGM reading 70 to 140 mg/dL \[3.9 to 7.8 mmol/L\]

    Time frame: From baseline through follow-up, maximum of 10 years

  12. Mean change from baseline in Time above tight range (TATR): >140 mg/dL (>7.8 mmol/L)

    CGM reading \>140 mg/dL (\>7.8 mmol/L)

    Time frame: From baseline through follow-up, maximum of 10 years

  13. Mean change from baseline in Time above range (TAR): >180 mg/dL (>10 mmol/L)

    CGM reading \>180 mg/dL (\>10 mmol/L)

    Time frame: From baseline through follow-up, maximum of 10 years

  14. Mean change from baseline in Time above range (TAR): >250 mg/dL (>13.9 mmol/L)

    CGM reading \>250 mg/dL (\>13.9 mmol/L)

    Time frame: From baseline through follow-up, maximum of 10 years

  15. Mean change from baseline in Time below range (TBR): <70 mg/dL (<3.9 mmol/L)

    CGM reading \<70 mg/dL (\<3.9 mmol/L)

    Time frame: From baseline through follow-up, maximum of 10 years

  16. Mean change from baseline in Time below range (TBR): <54 mg/dL (<3.0 mmol/L)

    CGM reading \<54 mg/dL (\<3.0 mmol/L)

    Time frame: From baseline through follow-up, maximum of 10 years

  17. Mean change from baseline in within-day glucose coefficient of variation

    Time frame: From baseline through follow-up, maximum of 10 years

  18. Mean change from baseline in between-day glucose coefficient of variation

    Time frame: From baseline through follow-up, maximum of 10 years

  19. Proportion of participants using insulin during the study period

    Continuous subcutaneous insulin infusion, insulin pump, or pump integrated with an automated insulin delivery system

    Time frame: Up to end of study, maximum of 10 years

  20. Proportion of participants using other glucose lowering therapies during the study period

    Time frame: Up to end of study, maximum of 10 years

  21. Change in EuroQol 5-Dimensions (EQ-5D) scores in adult and pediatric participants

    Time frame: From the first posttreatment visit after the last teplizumab infusion through follow-up, for a maximum of 10 years

  22. Change in Hospital Anxiety and Depression Scale (HADS) scores in adult participants

    Time frame: From the first posttreatment visit after the last teplizumab infusion through follow-up, for a maximum of 10 years

  23. Change in World Health Organization-Five Well-Being Index (WHO-5) scores in pediatric participants

    Time frame: From the first posttreatment visit after the last teplizumab infusion through follow-up, for a maximum of 10 years

  24. Change in Diabetes Distress Scale (DDS) scores in adult participants

    Time frame: From the time of Stage 3 T1D confirmation through follow-up, for a maximum of 10 years

  25. Change in Hypoglycemia Fear Survey-II (HFS-II) scores in adult and pediatric participants

    Time frame: From the time of Stage 3 T1D confirmation through follow-up, for a maximum of 10 years

  26. Annualized rate of hospitalizations due to T1D related disease and complications

    Time frame: Up to end of study, maximum of 10 years

  27. Annualized rate of emergency room visits related to T1D related disease and complications

    Time frame: Up to end of study, maximum of 10 years

07

Study locations

12 of 12 sites recruiting
  • Investigational Site Number: 8400006
    Washington D.C., District of Columbia 20010, United States
    Recruiting
  • Investigational Site Number: 8400003
    Atlanta, Georgia 30318-2538, United States
    Recruiting
  • Investigational Site Number: 8400004
    Atlanta, Georgia 30329-3102, United States
    Recruiting
  • Investigational Site Number: 8400001
    New York, New York 10016, United States
    Recruiting
  • Investigational Site Number: 8400002
    Syosset, New York 11791, United States
    Recruiting
  • Investigational Site Number: 8400005
    Sandy City, Utah 84093, United States
    Recruiting
  • Investigational Site Number: 2760004
    Hanover, 30173, Germany
    Recruiting
  • Investigational Site Number: 3760003
    Petah Tikva, 4920235, Israel
    Recruiting
  • Investigational Site Number: 3760002
    Ramat Gan, 52621, Israel
    Recruiting
  • Investigational Site Number: 3760001
    Ramat Gan, 5265601, Israel
    Recruiting
  • Investigational Site Number: 7840001
    Abu Dhabi, United Arab Emirates
    Recruiting
  • Investigational Site Number: 7840002
    Abu Dhabi, United Arab Emirates
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized, and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Oct 2035, 115 months after the start.

Of 50 industry-sponsored observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 115 months is above that.

Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2026
First posted
Jan 22, 2026
StartActual
Mar 19, 2026
Primary completionEst.
Oct 29, 2035
CompletionEst.
Oct 29, 2035
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added — first site in Germany
Show 2 added (1 United States, 1 Germany)
  • Investigational Site Number: 8400006 · Washington D.C., United States
  • Investigational Site Number: 2760004 · Hanover, Germany
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    2 sites added — first site in Germany
    Show 2 added (1 United States, 1 Germany)
    • Investigational Site Number: 8400006 · Washington D.C., United States
    • Investigational Site Number: 2760004 · Hanover, Germany
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07360080
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jan 22, 2026
Start date
Mar 19, 2026
Primary completion
Oct 29, 2035 (estimated)
Completion
Oct 29, 2035 (estimated)
Last update
Nov 9, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
contact-us@sanofi.com
800-633-1610 ext. Option 6

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion